Financial Performance - The company's operating revenue for 2020 was ¥110,993,349.65, a decrease of 4.05% compared to ¥115,683,338.13 in 2019[19] - The net profit attributable to shareholders in 2020 was -¥17,055,247.54, representing a decline of 282.25% from a profit of ¥9,358,190.19 in 2019[19] - The net cash flow from operating activities was -¥1,739,421.80, a decrease of 139.61% compared to ¥4,391,016.68 in 2019[19] - The basic earnings per share for 2020 was -¥0.06, down 300.00% from ¥0.03 in 2019[19] - Total assets at the end of 2020 were ¥507,416,635.12, a decrease of 3.95% from ¥528,275,795.87 at the end of 2019[19] - The net assets attributable to shareholders decreased by 27.28% to ¥109,620,523.97 at the end of 2020 from ¥150,733,210.98 at the end of 2019[19] - The company reported a significant increase in non-recurring losses, with the net profit excluding non-recurring items at -¥17,446,291.42 in 2020 compared to -¥1,113,865.72 in 2019, a decline of 1,466.28%[19] - The weighted average return on equity was -14.24% in 2020, down 21.16% from 6.92% in 2019[19] - Operating costs increased by 28.69% to ¥80,174,833.71, with the medical software and hardware segment accounting for 77.75% of total costs[54] - Management expenses rose by 23.1% to ¥27,593,392.46, primarily due to the expansion of the subsidiary Xintong NetEase[55] Revenue Breakdown - The company's operating revenue for 2020 was CNY 92,851,547.40 after deducting certain income, reflecting a decline compared to 2019[20] - In Q4 2020, the operating revenue reached CNY 41,983,952.51, showing a significant increase from Q2's CNY 18,027,592.40[24] - The company reported a net loss attributable to shareholders of ¥-6,269,305.3 in Q1 2020, compared to a profit of ¥19,994,995.0 in Q4 2019[59] - Software revenue accounted for ¥91,144,565.69, representing 82.12% of total revenue, down 17.13% from ¥114,815,195.79 in 2019[58] - Trade revenue increased significantly to ¥18,284,427.55, up 15.72% from ¥868,142.34 in 2019[58] Investments and Acquisitions - The company invested in a local agricultural company in Songyuan, Jilin Province, and plans to promote smart agriculture projects[29] - A new biological vaccine research company was established to capitalize on the growth opportunities in the domestic vaccine market[29] - The company invested 7.5 million RMB to acquire a 60% stake in WanFang MaiJie, which achieved approximately 18 million RMB in sales value by the end of 2020[34] - The company signed a partnership agreement to establish a joint venture, investing ¥5,000,000, with a 55% stake in WanFang BaiAo[50] - The company plans to acquire 80% of Beijing Furuijun'an Technology Co., gaining access to a 20-valent pneumonia conjugate vaccine technology[51] Research and Development - The company's R&D investment amounted to ¥12,315,976.12, with capitalized R&D costs of ¥3,237,713.35[55] - R&D expenses increased by 17.61% to ¥9,078,262.77 in 2020, up from ¥7,719,159.05 in 2019, reflecting increased investment in R&D by Xintong NetEase[70] - The number of R&D personnel grew by 51.85% to 246 in 2020, compared to 162 in 2019, indicating a focus on enhancing R&D capabilities[73] - The company completed 11 new R&D projects in 2020, enhancing its product line and market competitiveness[71] - The company is currently developing several systems, including a Nursing Management System and an Emergency Management System, aimed at improving healthcare efficiency[72] Strategic Focus and Market Position - The company aims to enhance its sustainable operational capacity through diversification strategies, including investments and mergers[29] - The company focuses on providing healthcare information technology solutions, becoming a significant player in the southwestern region of China[30] - The company is transitioning its strategic focus towards high-tech fields, particularly in the vaccine and bioproducts sector[50] - The company aims to expand its operations in 2021 by focusing on a full industrial chain modern agricultural company, emphasizing grain storage, entrusted planting, and agricultural logistics[35] - The company is actively pursuing market expansion and technological advancements in the biopharmaceutical sector[107] Challenges and Risks - The company faces liquidity pressure due to long accounts receivable cycles from its primary clients, which are mostly state-owned medical institutions[32] - The company is facing risks from macroeconomic fluctuations and policy changes, which could adversely affect its financial performance[120] - The company recognizes the risks associated with single business operations and is pursuing a diversified business strategy through investments and acquisitions[120] - The company faces risks in new product development due to the complex and high-risk nature of biopharmaceuticals, which require extensive clinical trials and regulatory approvals[121] Corporate Governance and Compliance - The company has established measures to prevent conflicts of interest and ensure fair transactions with related parties[131] - The company has committed to maintaining an independent financial department and accounting system, ensuring no shared bank accounts with controlling entities[134] - The company has pledged to minimize transactions with controlling entities, adhering to principles of openness, fairness, and justice[134] - The company has engaged in 14 investor communication activities during the reporting period, focusing on various operational updates[123] - The company has not disclosed any significant undisclosed information during its investor communications[123]

万方城镇投资发展股份有限公司 2021 年第一季度报告全文 万方城镇投资发展股份有限公司 2021 年第一季度报告 2021 年 04 月 1 万方城镇投资发展股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人张晖、主管会计工作负责人董威亚及会计机构负责人(会计主管 人员)董威亚声明：保证季度报告中财务报表的真实、准确、完整。 2 万方城镇投资发展股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 30,359,764.25 | 22,904,521.61 | 32.55% | | 归属于上市公司股东的净利润（元） | 15,940,295.68 | -6 ...

Financial Performance - The company's operating revenue for 2020 was ¥110,993,349.65, a decrease of 4.05% compared to ¥115,683,338.13 in 2019[19]. - The net profit attributable to shareholders for 2020 was -¥17,055,247.54, representing a decline of 282.25% from a profit of ¥9,358,190.19 in 2019[19]. - The net cash flow from operating activities was -¥1,739,421.80, a decrease of 139.61% compared to ¥4,391,016.68 in 2019[19]. - The basic earnings per share for 2020 was -¥0.06, down 300.00% from ¥0.03 in 2019[19]. - Total assets at the end of 2020 were ¥507,416,635.12, a decrease of 3.95% from ¥528,275,795.87 at the end of 2019[19]. - The net assets attributable to shareholders decreased by 27.28% to ¥109,620,523.97 at the end of 2020 from ¥150,733,210.98 at the end of 2019[19]. - The company reported a significant increase in the net profit attributable to shareholders after deducting non-recurring gains and losses, which was -¥17,446,291.42 in 2020 compared to -¥1,113,865.72 in 2019, a decline of 1,466.28%[19]. - The weighted average return on net assets was -14.24% in 2020, down 21.16% from 6.92% in 2019[19]. - The company recorded an operating cost of ¥80,174,833.71, an increase of 28.69% year-on-year[54]. - The net profit attributable to the parent company was -¥17,055,247.54, a decline of 282.25% year-on-year[54]. Revenue Breakdown - The company’s revenue after deducting hardware leasing income was ¥110,961,638.72 in 2020, compared to ¥115,683,338.13 in 2019[20]. - Software revenue accounted for ¥91,144,565.69, representing 82.12% of total revenue, down 17.13% from ¥114,815,195.79 in 2019[58]. - Trade revenue increased significantly to ¥18,284,427.55, up 15.72% from ¥868,142.34 in 2019[58]. - The company’s revenue from grain trading reached ¥18,110,091.32, marking a 100% increase from zero in 2019[62]. Cash Flow and Investments - The cash flow from operating activities was -¥1,739,421.80, indicating challenges in operational cash generation[55]. - The net cash flow from operating activities showed a recovery in the fourth quarter with 66,728,880.94 yuan, after negative cash flows in the first three quarters[24]. - The net cash flow from investment activities was 10,269,186.83 CNY, mainly resulting from the proceeds from the equity transfer of a subsidiary[79]. - The net cash flow from financing activities was 2,688,599.70 CNY, primarily due to borrowings and repayments of principal and interest by the subsidiary Xintong NetEase[79]. - The total cash inflow from operating activities increased by 26.45% to 308,465,120.58 CNY compared to the previous year[78]. - The total cash outflow from operating activities increased by 29.50% to 310,204,542.38 CNY compared to the previous year[78]. Research and Development - The company's R&D investment amounted to ¥12,315,976.12, with capitalized R&D costs of ¥3,237,713.35[55]. - R&D expenses increased by 17.61% to ¥9,078,262.77 in 2020 from ¥7,719,159.05 in 2019, reflecting increased investment in R&D by Xintong NetEase[70]. - The number of R&D personnel grew by 51.85% to 246 in 2020 from 162 in 2019, with R&D personnel accounting for 39.61% of the total workforce[73]. - The company initiated 11 new R&D projects in 2020, including the Nursing Management System and Emergency Management System, aimed at enhancing healthcare service efficiency[72]. - The completed projects include the Nursing Whiteboard V2.0 and the DRGs Hospital Decision Support System, which improve operational stability and service quality[72]. Strategic Initiatives - The company plans to expand its operations in 2021, focusing on a full industrial chain modern agriculture model, emphasizing grain storage, entrusted planting, and agricultural logistics[35]. - The company is actively working on divesting non-strategic assets, including a 55.30% stake in 信通网易[52]. - The company aims to develop smart agriculture through integrated management of planting, storage, sales, and logistics[52]. - The company is focusing on the development and promotion of agricultural technology, which may enhance operational efficiency in the long term[89]. - The company is committed to improving supply chain management, which is crucial for enhancing operational efficiency and reducing costs[89]. Market Position and Competition - The competitive landscape in the medical IT market is intensifying with both domestic and international players, including major foreign companies like Intel and IBM entering the market[32]. - The company’s subsidiary, Xintong Net, is a leading provider of medical health information solutions in the western region of China, emphasizing the importance of "Internet + Medical" during the COVID-19 pandemic[30]. - The company has established a complete software product line with independent intellectual property rights, categorized into three main types: hospital information platforms, population health information platforms, and mobile internet medical platforms[33]. - The company is recognized as a key supplier of health information products in Sichuan Province and is one of only 20 companies nationwide involved in the standardization of electronic medical record hospital information systems[38]. Asset Management and Restructuring - The company has engaged in significant equity investments during the reporting period, although specific details were not provided[85]. - The company is in the process of a major asset restructuring, involving the sale of 90% of its stake in a subsidiary and the cash purchase of another company[132]. - The company has committed to divesting its land development business to avoid competition and protect shareholder interests, with specific subsidiaries to be transferred[130]. - The company has established independent financial departments and accounting systems, ensuring no shared bank accounts with controlling entities[134]. Shareholder and Governance Issues - The company reported a net profit attributable to the parent company of -17.06 million yuan for 2020, with an ending undistributed profit of -34.81 million yuan, resulting in no profit distribution or capital reserve transfer for the year[126]. - The company has not distributed dividends for the past three years, with net profits of 9.36 million yuan in 2019 and -14.75 million yuan in 2018[128]. - The controlling shareholder, Beijing Wanfang Yuan, holds 116,600,000 shares, accounting for 37.69% of the total shares, with all shares pledged and frozen[184]. - The company has no impact on its governance structure or ongoing operations due to the pledge and freeze of shares[181]. Future Outlook - The company plans to expand its product pipeline into vaccines, medical devices, and innovative biopharmaceuticals, aiming to become a comprehensive biopharmaceutical company[107]. - The company is actively developing its biopharmaceutical business, with ongoing vaccine research and production expected to significantly boost profitability in the next 2-5 years[117]. - The company is committed to strengthening international cooperation in key technology areas to address critical challenges in the biopharmaceutical sector[103]. - The company aims to enhance its agricultural supply chain by integrating smart agriculture concepts and improving production efficiency, thereby increasing farmer income and agricultural output[116].

Financial Performance - Operating revenue for the reporting period was CNY 28,077,283.13, down 45.69% year-on-year, with total operating revenue from the beginning of the year to the reporting period at CNY 69,009,397.14, a decrease of 26.11%[7][15] - Net profit attributable to shareholders of the listed company was CNY -833,374.71 for the reporting period, an increase of 86.57% year-on-year, with a total net profit of CNY -12,250,459.83 from the beginning of the year to the reporting period, a decrease of 15.17%[7] - The company reported a total operating cost of CNY 84,170,778.30, a decrease of 18.51% year-on-year[15] - Total operating revenue for the third quarter was CNY 28,077,283.13, a decrease from CNY 51,696,111.27 in the previous period[39] - Total operating revenue for the third quarter was CNY 69,009,397.14, a decrease of 26.1% compared to CNY 93,399,377.21 in the same period last year[47] - Net profit for the third quarter was CNY 163,207.54, compared to a net loss of CNY 6,068,964.96 in the previous year[41] - The company reported a net profit attributable to minority shareholders of CNY 996,582.25, while the profit attributable to the parent company was a loss of CNY -833,374.71[41] - The total comprehensive income for the third quarter was CNY 163,207.54, compared to a comprehensive loss of CNY 6,068,964.96 in the same period last year[42] - The net profit for the third quarter of 2020 was -14,349,951.39 CNY, compared to -8,935,556.30 CNY in the same period last year, reflecting a significant increase in losses[48] - The total comprehensive income for the third quarter was -14,349,951.39 CNY, compared to -8,935,556.30 CNY in the previous year[49] Cash Flow and Assets - The net cash flow from operating activities was CNY -660,845.49, a decrease of 146.85% compared to the same period last year, with a total of CNY -68,468,302.74 from the beginning of the year to the reporting period, a decrease of 725.32%[7][15] - As of September 30, 2020, the company's cash and cash equivalents decreased to RMB 6,159,501.07 from RMB 62,659,230.82 at the end of 2019, representing a decline of approximately 90.2%[31] - The total cash and cash equivalents at the end of the period decreased to 6,159,501.07 from 122,083,893.25 in the previous period[57] - The cash flow from operating activities showed a net outflow of -68,468,302.74 CNY, worsening from -8,295,974.95 CNY year-over-year[56] - The company received cash inflows from operating activities totaling 148,411,818.96 CNY, down from 179,506,210.88 CNY in the previous year[56] - The cash inflow from investment activities was 11,000,000.00, up from 2,965,000.00 in the previous period[58] - The cash outflow from financing activities was 2,038,460.95, compared to 21,735,224.58 in the previous period[60] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,513[11] - The largest shareholder, Beijing Wanfangyuan Real Estate Development Co., Ltd., held 37.69% of the shares, totaling 116,600,000 shares[11] Investments and Subsidiaries - The company plans to transfer 55.30% equity of its subsidiary, Chengdu Xintong Weiyi Medical Technology Co., Ltd., for an undisclosed amount after completing the audit and evaluation[18] - The company invested RMB 5,000 million to establish a joint venture, Jilin Wanfang Bai'ao Biotechnology Co., Ltd., with a 55% ownership stake[19] - The company signed an agreement to increase its investment in Qian'an Wanda Grain Storage Co., Ltd. by RMB 750 million, raising its ownership to 60%[20] - The company is actively working on the equity transfer agreement with Yue Yifeng for the sale of 40% equity in Yihuan Medical, priced at RMB 47 million[17] - The company incurred an investment loss of CNY -4,525,783.88, primarily due to increased losses from an associated subsidiary[15] - The company incurred investment losses of -4,525,783.88 CNY during the third quarter, compared to a loss of -54,400.04 CNY in the same period last year[48] Liabilities and Equity - Total assets at the end of the reporting period were CNY 470,993,983.97, a decrease of 10.84% compared to the end of the previous year[7] - Total liabilities decreased to CNY 260,216,188.62 from CNY 303,148,049.13, representing a reduction of about 14.2%[33] - Current liabilities totaled CNY 251,103,546.35, down from CNY 292,998,717.11, indicating a decrease of approximately 14.4%[33] - The total owner's equity decreased to CNY 210,777,795.35 from CNY 225,127,746.74, reflecting a decline of approximately 6.4%[34] - The company reported a significant increase in cash outflow for operating activities, totaling 63,610,474.68, compared to 29,776,032.64 in the previous period[58] - The company holds long-term equity investments valued at CNY 274,434,914.10, indicating a significant investment strategy[68] Expenses - Management expenses increased by 21.65% year-on-year to CNY 18,127,752.94, primarily due to increased management fees from a subsidiary[15] - Research and development expenses amounted to CNY 8,723,643.20, mainly for R&D investments in a subsidiary[15] - Research and development expenses increased to CNY 2,081,072.05, a significant rise from CNY 276,057.32 in the same quarter last year[40] - The company’s sales expenses rose to CNY 3,757,460.30, compared to CNY 3,366,853.72 in the previous year[40] - The company incurred a financial expense of CNY -805,114.80, a decrease from CNY 5,392,585.64 in the previous year[40] - The management expenses for the third quarter were 2,996,484.79 CNY, slightly down from 3,368,661.00 CNY in the previous year[51] Compliance and Reporting - The company has not engaged in any securities or derivative investments during the reporting period[23][24] - There are no overdue commitments from the actual controller, shareholders, or related parties during the reporting period[22][27] - The company has not reported any violations regarding external guarantees during the reporting period[26] - The report for the third quarter was not audited, indicating that the figures may be subject to change upon final audit[71] - The company adjusted its financial statements in accordance with new revenue and leasing standards, impacting the balance sheet[61] - The company adopted the new revenue recognition standard starting January 1, 2020, impacting financial reporting[71]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥40,932,114.01, a decrease of 1.85% compared to ¥41,703,265.94 in the same period last year[17]. - The net profit attributable to shareholders was a loss of ¥11,417,085.12, representing a decline of 157.69% from a loss of ¥4,430,466.88 in the previous year[17]. - The net cash flow from operating activities was negative at ¥67,807,457.25, a significant increase in loss of 598.57% compared to ¥-9,706,553.79 in the same period last year[17]. - The basic earnings per share were ¥-0.0369, down 158.04% from ¥-0.0143 in the previous year[17]. - Total assets at the end of the reporting period were ¥473,675,556.26, a decrease of 10.34% from ¥528,275,795.87 at the end of the previous year[17]. - The net assets attributable to shareholders decreased by 7.57% to ¥139,316,125.86 from ¥150,733,210.98 at the end of the previous year[17]. - The company reported total revenue of ¥40,932,114.01, a decrease of 1.85% compared to the same period last year[41]. - The net profit attributable to the parent company was a loss of ¥11,417,085.12, an increase in loss of 157.69% year-on-year[41]. - Operating costs totaled ¥28,612,540.83, an increase of 25.32% compared to the previous year[41]. - The company reported a net loss of 4,855,000,000 CNY, reflecting a decrease of 318,400,000 CNY compared to the previous period[150]. - The total comprehensive income for the period amounted to 7,092,776,000 CNY, with a decrease of 4,378,224,000 CNY from the previous period[150]. - The company reported a significant increase in research and development expenses, totaling CNY 6,642,571.15, compared to CNY 5,824,748.41 in the previous year[130]. - The company reported a net profit for the first half of 2020 of -14,513,158.93 CNY, compared to -2,866,591.34 CNY in the same period of 2019, indicating a significant increase in losses[132]. - The total comprehensive income for the first half of 2020 was -14,513,158.93 CNY, compared to -2,918,833.94 CNY in the previous year, reflecting a worsening financial position[133]. Operational Strategy - In the first half of 2020, the company focused on optimizing asset allocation and restructuring internal management to enhance operational efficiency amid the challenges posed by COVID-19 and economic downturn[24]. - The company plans to gradually divest from its primary land development business to concentrate resources on its core medical information services[27]. - The company is in a strategic transition phase, gradually divesting from land development-related businesses to focus on its core operations[38]. - The company plans to enhance its operational capabilities and mitigate risks associated with entering new business areas through comprehensive system design and quality control management[65]. - The company aims to improve its financial performance by optimizing its capital structure and enhancing operational efficiency[149]. Market Presence and Product Development - The company has developed a comprehensive software product line with complete independent intellectual property rights, covering nearly 30% of secondary and above hospitals in Sichuan Province and 90% in Qinghai Province[27]. - The company’s main products include an electronic medical record-based hospital information platform, a population health information platform, and a mobile internet medical platform, serving various hospitals and health management institutions[27]. - The company has expanded its market presence to provinces including Jilin, Guangxi, Guangdong, Hainan, and Shaanxi during the reporting period[27]. - The company has established a marketing and service network across over 10 cities in China, focusing on enhancing customer experience and building successful internet hospital case studies[34]. - The company plans to continue expanding its market presence and developing new products in the upcoming quarters[149]. Research and Development - Research and development investment amounted to ¥7,057,643.16, with a capitalized amount of ¥415,072.01[42]. - The company has obtained 20 new software copyrights in the first half of 2020, reflecting its commitment to innovation and product development[33]. - The company has a stable core research and development team dedicated to expanding its product portfolio, with a deep understanding of the healthcare industry's management and operational processes[36]. Financial Management and Risks - The company anticipates significant risks due to macroeconomic fluctuations and changes in national policies, particularly in light of the ongoing COVID-19 pandemic[64]. - The company is facing challenges in its land development projects due to issues such as demolition delays and uncertain profit recognition timelines[27]. - The company’s cash flow management strategies need to be reassessed due to the significant cash outflows and reduced cash reserves[144]. - The company faces risks related to long development cycles in land leveling and urban infrastructure investment, including funding and policy stability risks[65]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares[5]. - The total number of shares remains at 309,400,000, with no changes during the reporting period[101]. - The largest shareholder, Beijing Wanfangyuan Real Estate Development Co., Ltd., holds 37.69% of the shares, totaling 116,600,000 shares, which are pledged and frozen[104]. - The controlling shareholder, Beijing Wanfangyuan Real Estate Development Co., Ltd., has had shares frozen due to debt obligations, affecting 25.74 million shares since October 10, 2018[76]. - The company did not implement any equity incentive plans or employee stock ownership plans during the reporting period[78]. Compliance and Governance - The financial report for the half-year period was not audited[120]. - The financial report was approved by the board of directors on August 27, 2020, ensuring compliance with accounting standards[162]. - The company has maintained its continuous operation capability without significant doubts for the next 12 months[161]. - The accounting policies followed are in accordance with the enterprise accounting standards, ensuring the accuracy of financial reporting[162]. Asset Management - Cash and cash equivalents at the end of the reporting period were ¥4,661,818.73, a decrease of 15.27% compared to the previous year[54]. - Accounts receivable increased to ¥79,321,066, representing 16.75% of total assets, while inventory decreased slightly to 28.81% of total assets[55]. - The company sold 40% of its stake in Yihuan Medical for ¥47 million, aimed at optimizing resource allocation and improving management efficiency[59][60]. - The company reported a decrease in fixed assets to ¥3,482,766.64, which is 0.74% of total assets, reflecting a slight increase from the previous year[55]. Legal and Regulatory Matters - The company has not experienced any major litigation or arbitration matters during the reporting period[74]. - There were no significant related party transactions during the reporting period, including daily operational transactions, asset or equity acquisitions, and joint investments[79][80][81].

证券代码：000638 证券简称：万方发展 公告编号：2020-030 万方城镇投资发展股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，万方城镇投资发展股份有限公司（以下 简称 "公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限 公司共同举办的"提高公司质量 做受尊敬的上市公司--2020 年吉林辖区上市公 司投资者网上集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景·路演天下"网站（http://rs.p5w.net）参与公司本次投资 者集体接待日活动，时间为 2020 年 8 月 21 日（周五）15:30 至 17:00。 届时公司总经理章寒晖先生、董事会秘书郭子斌女士、财务总监董威亚先生 将通过网络在线问答互动的形式，与投资者就公司治理、发展经营情况、融资情 况和可持续发展等投资者关注的问题进行交流。期间，公司高管将全程在线，实 时回答投资者的提问。 欢迎广大投资者积 ...

Financial Performance - The company's operating revenue for the first quarter of 2020 was CNY 22,904,521.61, representing a 50.51% increase compared to CNY 15,218,371.02 in the same period last year[7]. - The net profit attributable to shareholders of the listed company was a loss of CNY 6,269,305.38, which is a 209.84% increase in loss compared to a loss of CNY 2,023,390.49 in the previous year[7]. - The net loss for Q1 2020 was CNY 10,056,799.43, compared to a net loss of CNY 2,658,843.76 in the same period last year[39]. - Total comprehensive income for the period was also a loss of ¥1,210,590.67, reflecting the same trend as net profit[44]. - Basic and diluted earnings per share for Q1 2020 were both -0.0203, compared to -0.0065 in the previous year[40]. Cash Flow - The net cash flow from operating activities was CNY -10,407,171.63, showing a slight improvement of 1.00% from CNY -10,511,994.70 in the same period last year[7]. - The company’s cash flow from financing activities resulted in a net outflow of ¥437,357.88, compared to a larger outflow of ¥10,615,297.13 in the previous period[48]. - The net cash flow from investment activities was CNY 5,805,900.00, primarily due to the receipt of funds from the transfer of subsidiary equity[15]. - The net cash flow from investment activities amounted to ¥6,000,000 in Q1 2020[51]. - The ending balance of cash and cash equivalents was ¥51,089,625.89, a decrease from the beginning balance of ¥50,297,418.14[51]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 510,447,389.47, a decrease of 3.37% from CNY 528,275,795.87 at the end of the previous year[7]. - The company's total assets amounted to RMB 510,447,389.47, a decrease from RMB 528,275,795.87 on December 31, 2019[29][30]. - The company's total liabilities as of March 31, 2020, were RMB 295,376,442.16, down from RMB 303,148,049.13[31]. - The total liabilities decreased from CNY 226,833,666.38 to CNY 222,614,172.56 during the same period[35]. - The company's equity attributable to the parent company decreased from CNY 150,733,210.98 to CNY 144,463,905.60[34]. Expenses - The total operating costs for the first quarter amounted to CNY 35,741,447.40, which is a 102.76% increase compared to the previous year[14]. - Management expenses increased by 168.48% to CNY 11,059,951.42, primarily due to an increase in management personnel at a subsidiary[14]. - The company reported a significant increase in management expenses, rising from CNY 4,119,497.37 to CNY 11,059,951.42[38]. - Research and development expenses decreased by 62.92% to CNY 1,149,648.98, mainly due to reduced R&D spending at a subsidiary[14]. - Financial expenses totaled ¥150,968.66, a significant decrease from a negative financial expense of ¥1,799,348.81 in the prior period[43]. Shareholder Information - The company had a total of 36,200 common shareholders at the end of the reporting period[10]. - The company agreed to sell a 40% stake in Chengdu Yihuan Medical Technology Co., Ltd. for RMB 47 million (approximately $6.7 million) on September 29, 2019[16]. - The company signed a share transfer agreement on February 12, 2020, to transfer its 40% stake in Yihuan Medical for RMB 47 million[17]. Compliance and Reporting - The company reported no significant non-compliance issues regarding external guarantees during the reporting period[24]. - There were no securities investments or entrusted financial management activities reported during the period[19][20]. - The first quarter report for 2020 was not audited[58]. - The company adopted new revenue and leasing standards starting January 1, 2020, impacting financial reporting[54].

Financial Performance - The company's operating revenue for 2019 was ¥115,683,338.13, a decrease of 2.61% compared to ¥118,788,735.89 in 2018[19] - The net profit attributable to shareholders in 2019 was ¥9,358,190.19, a significant increase of 106.35% from a loss of ¥147,473,832.54 in 2018[19] - The net cash flow from operating activities improved to ¥4,391,016.68, up 106.47% from a negative cash flow of ¥67,888,803.33 in the previous year[19] - The basic earnings per share for 2019 was ¥0.03, compared to a loss of ¥0.48 per share in 2018, marking a 106.25% improvement[19] - Total assets decreased by 29.39% to ¥528,275,795.87 at the end of 2019, down from ¥748,156,109.10 at the end of 2018[19] - The net assets attributable to shareholders increased by 15.41% to ¥150,733,210.98 at the end of 2019, compared to ¥130,612,092.63 at the end of 2018[19] - The weighted average return on equity for 2019 was 6.92%, a recovery of 84.64% from -77.72% in 2018[19] - The company reported a net profit excluding non-recurring gains and losses of -¥1,113,865.72, a decrease of 99.25% from -¥147,570,599.44 in 2018[19] Business Operations - The company has not made any changes to its main business since its listing[17] - The main business remains in medical information software development and land development, with no significant changes in product offerings[29] - The company aims to provide innovative healthcare information solutions, enhancing patient experience and health levels in the region[29] - The company is focusing on optimizing asset allocation by divesting non-strategic assets and restructuring internal management to enhance operational efficiency[29] Market Position and Strategy - The government has introduced supportive policies for the internet healthcare sector, which is expected to drive growth in the industry[30] - The competitive landscape in the medical IT market is intensifying with both domestic and international players entering the market[32] - The company is committed to leveraging favorable tax policies and government support to enhance its market position in the software industry[30] - The company has established a strong brand presence as a key supplier of health information products in Sichuan Province and has received recognition for its solutions from over a thousand medical institutions nationwide[36] Research and Development - Research and development expenses amounted to ¥12,335,121.13, with capitalized R&D costs of ¥4,615,962.00[53] - The company has initiated six new R&D projects, including a Patient Follow-up Management System and a Clinical Medical Testing APP Management System, all currently in development[69] - The R&D investment as a percentage of operating revenue increased to 10.66% from 9.44%[69] - The company completed several R&D projects, including the Clinical Testing Report Intelligent Review System and the Endoscope Cleaning Management System[70] Subsidiaries and Investments - The company’s subsidiary, Xintong Net, is one of the earliest providers of healthcare information services in Western China, focusing on system integration and software development[30] - The company completed the sale of 100% equity in a subsidiary in September 2019 and 70% equity in another subsidiary in December 2019, affecting the consolidation scope[63] - The company reported a revenue of approximately 214.17 million CNY from its subsidiary Chengdu Xintong Network Medical Technology Development Co., with a net profit of about 27.20 million CNY for the reporting period[97] Financial Management - The company is focused on market expansion and enhancing its investment capabilities in the healthcare sector[91] - The company plans to implement new strategies to improve operational efficiency and shareholder value[90] - The company is actively pursuing opportunities for mergers and acquisitions to strengthen its market position[91] - The company has established a partnership with a qualified accounting firm to ensure compliance and transparency in its financial reporting[92] Shareholder Relations - The company is actively enhancing investor relations through multiple communication channels to improve its brand image in the capital market[49] - The company has committed to ensuring that the interests of minority shareholders are protected during the equity transfer process[93] - The company aims to meet the conditions for profit distribution in the future after offsetting previous losses and achieving positive undistributed profits[112] Compliance and Governance - The company is committed to maintaining transparency and compliance with regulatory requirements in its financial reporting[91] - The company ensures the independence of its financial department and accounting system, prohibiting interference from controlling shareholders[119] - The company has undertaken to avoid any related party transactions that could harm the interests of minority shareholders[116] Future Outlook - The company provided guidance for 2020, projecting a revenue growth of 10% to 1.32 billion[199] - New product launches are expected to contribute an additional 200 million in revenue in the upcoming fiscal year[199] - The company is considering strategic acquisitions to bolster its market position, with a budget of 100 million allocated for potential deals[199] - The management emphasized a focus on improving operational efficiency, targeting a 3% reduction in costs by the end of 2020[199]

Financial Performance - The company's operating revenue for Q1 2020 was ¥22,904,521.61, representing a 50.51% increase compared to ¥15,218,371.02 in the same period last year[7]. - The net profit attributable to shareholders was -¥6,269,305.38, a 209.84% increase in loss compared to -¥2,023,390.49 in the previous year[7]. - The net cash flow from operating activities was -¥10,407,171.63, showing a slight improvement of 1.00% from -¥10,511,994.70 year-on-year[7]. - The total operating revenue for Q1 2020 was CNY 22,904,521.61, compared to CNY 15,218,371.02 in the previous period[39]. - Net loss for Q1 2020 was CNY 10,056,799.43, compared to a net loss of CNY 2,658,843.76 in the same period last year[41]. - The company incurred a net loss of 1,210,590.67 CNY, a decline from a profit of 158,751.92 CNY in the previous period[46]. - Total comprehensive income for the current period was -1,210,590.67 CNY, compared to 158,751.92 CNY in the previous period[46]. Assets and Liabilities - Total assets at the end of the reporting period were ¥519,498,048.92, a decrease of 3.32% from ¥537,326,455.32 at the end of the previous year[7]. - As of March 31, 2020, the company's total assets amounted to RMB 519.50 million, a decrease from RMB 537.33 million as of December 31, 2019[30][32]. - The company's current assets totaled RMB 308.63 million, down from RMB 319.15 million at the end of 2019[30]. - The company's total liabilities were RMB 294.19 million, down from RMB 301.96 million at the end of 2019[33]. - The total assets as of March 31, 2020, were CNY 338,799,976.23, down from CNY 344,230,060.72 at the end of 2019[36]. - Total liabilities decreased to CNY 222,602,844.02 from CNY 226,822,337.84[37]. - The total equity attributable to shareholders of the parent company was CNY 116,197,132.21, down from CNY 117,407,722.88[37]. Cash Flow - The net cash flow from investment activities was ¥5,805,900.00, primarily from the proceeds of a subsidiary's equity transfer[15]. - The company received 6,000,000.00 CNY from investment recoveries during the current period[49]. - The company’s total cash outflow from financing activities was 5,197,357.88 CNY, compared to 15,615,297.13 CNY in the previous period[50]. - The net cash flow from investment activities was CNY 6,000,000.00 for the first quarter of 2020[53]. - The net cash flow from financing activities was negative at CNY -14,526,164.39, primarily due to debt repayment of CNY 13,800,000.00 and dividend payments of CNY 726,164.39[53]. Expenses - The total operating costs for the period were ¥35,741,447.40, which is a 102.76% increase compared to the previous year, primarily due to increased costs from subsidiaries[14]. - Management expenses rose by 168.48% to ¥11,059,951.42, attributed to an increase in management personnel at a subsidiary[14]. - Research and development expenses decreased by 62.92% to ¥1,149,648.98, mainly due to reduced R&D spending at a subsidiary[14]. - The company reported a significant increase in management expenses, rising to CNY 11,059,951.42 from CNY 4,119,497.37[40]. - The company paid 16,871,356.68 CNY for goods and services, an increase from 7,327,894.33 CNY in the previous period[49]. - The company’s financial expenses amounted to 150,968.66 CNY, a significant improvement from -1,799,348.81 CNY in the previous period[45]. Shareholder Information - The company reported a total of 36,200 common shareholders at the end of the reporting period[10]. - The company agreed to sell 40% of its stake in Chengdu Yihuan Medical Technology Co., Ltd. for RMB 47 million (approximately $6.7 million) on September 29, 2019[16]. - The board approved the share transfer agreement with Yue Yifeng on February 12, 2020, for the same 40% stake at the same price of RMB 47 million[17]. - The company plans to transfer 55.30% of its stake in its subsidiary Chengdu Xintong Weiy Medical Technology Development Co., Ltd. after completing the audit and evaluation[17]. Accounting Changes - The company adopted new revenue and leasing standards starting January 1, 2020, impacting financial reporting[58].

Financial Performance - Operating revenue for the reporting period was CNY 51,696,111.27, an increase of 162.97% year-on-year, while total operating revenue from the beginning of the year to the reporting period was CNY 93,399,377.21, up 42.33% year-on-year[7][15] - Net profit attributable to shareholders was a loss of CNY 6,206,337.93, a decline of 113.24% year-on-year, with a cumulative loss of CNY 10,636,804.80 for the year, down 45.06% year-on-year[7][15] - The company reported a net loss of CNY 329,137,683.79 in retained earnings, compared to a loss of CNY 318,479,586.45 in the previous period[36] - The company reported a basic and diluted earnings per share of -0.0199, compared to -0.0094 in the previous period, indicating a decline in profitability per share[45] - The total comprehensive income for the current period was -¥6,068,964.96, compared to -¥3,647,073.23 in the previous period, indicating a worsening overall financial performance[45] - The net profit for the period was a loss of ¥8,935,556.30, an improvement from a loss of ¥23,023,599.60 in the same period last year, reflecting a reduction in losses of approximately 61%[51] - The company reported a gross profit margin of approximately -10.4% for the current period, compared to -34.2% in the previous period[49] Cash Flow - The net cash flow from operating activities was negative CNY 8,295,974.95, reflecting a 91.25% increase in cash outflow compared to the same period last year[7][15] - Cash generated from operating activities was ¥95,234,740.15, compared to ¥86,865,906.98 in the previous period, reflecting an increase of approximately 9.8%[58] - The net cash flow from operating activities was -8,295,974.95 CNY, an improvement from -94,845,921.13 CNY in the previous period, indicating a significant reduction in cash outflow[59] - Total cash inflow from operating activities was 179,506,210.88 CNY, compared to 141,686,697.69 CNY in the previous period, reflecting a year-over-year increase of approximately 26.6%[59] - Cash outflow from operating activities totaled 187,802,185.83 CNY, down from 236,532,618.82 CNY, showing a decrease of about 20.6%[59] Assets and Liabilities - Total assets at the end of the reporting period were CNY 736,680,420.64, a decrease of 1.53% compared to the end of the previous year[7] - Total liabilities decreased from CNY 553,171,186.64 to CNY 525,648,086.83, a decline of about 5%[35] - Owner's equity increased from CNY 194,984,922.46 to CNY 211,032,333.81, an increase of approximately 8%[36] - Current liabilities decreased from CNY 541,639,601.62 to CNY 515,153,191.56, a reduction of about 5%[35] - Non-current liabilities decreased from CNY 11,531,585.02 to CNY 10,494,895.27, a decrease of approximately 9%[35] Expenses - Management expenses decreased by 66.45% year-on-year to CNY 14,901,670.83, primarily due to the disposal of a subsidiary[15] - Research and development expenses amounted to CNY 6,101,195.73, mainly for the R&D investments of a subsidiary[15] - Sales expenses increased by 156.22% year-on-year to CNY 7,377,693.71, driven by increased sales costs at a subsidiary[15] - Financial expenses rose by 82.61% year-on-year to CNY 9,043,735.76, mainly due to exchange rate losses[15] Corporate Actions - The company established a wholly-owned subsidiary with an investment of CNY 10 million to enhance sustainable operations and profitability[16] - The company terminated the major asset restructuring plan for Beijing Guishi Information Technology Co., Ltd. after over a year of consideration, citing difficulties in achieving the acquisition through a combination of share issuance and cash payment[17] - The company sold 100% equity of its subsidiary WanFang Development (Hong Kong) for RMB 200,000, with the transaction completed on August 23, 2019[18] - The company plans to deregister Chengdu WanFang Yihuan Medical Management Co., Ltd. to optimize resource allocation and reduce management costs[20] - The company signed a framework agreement to sell 40% equity of Chengdu Yihuan Medical Technology Co., Ltd. for RMB 47 million on September 29, 2019[21] Financial Position - Total assets decreased from CNY 748,156,109.10 to CNY 736,680,420.64, a decline of approximately 2%[34] - The company’s capital reserve increased from CNY 134,857,563.82 to CNY 154,475,308.11, an increase of about 15%[36] - The company’s short-term borrowings increased from CNY 10,500,000.00 to CNY 13,000,000.00, an increase of approximately 24%[34] - The company has a goodwill amounting to CNY 83,769,371.29, indicating potential for future earnings[67] Other Financial Information - The company has implemented new financial instrument standards since January 1, 2019, which will not affect previous financial statements[69] - The third quarter report was not audited[74]